AnaptysBio, Inc. (ANAB)
Develops antibody drugs to treat autoimmune and inflammatory diseases like rheumatoid arthritis and psoriasis.
$53.01-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+222.0%
The outlook
ANAB trades at $53.01, positioned roughly two-thirds of the way up its 52-week range. Analysts overwhelmingly favor the stock with a Strong Buy consensus, and their average price target sits about 64% above the current price. The stock shows mixed momentum against its moving averages, suggesting some near-term uncertainty despite the bullish analyst view.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 11 analysts
Price trendMixed vs its moving averages
52-week range68% of the way from its 52-week low to high
Price targetAvg target +64% vs current price
Analyst price target
~12-month · 11 analysts$87.09average target+64.3% vs now
Now $53.01
Low $70.00High $140.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.57B
52-wk high
$72.36
52-wk low
$11.40
50-day avg
$58.35
200-day avg
$41.61
Trailing P/E
—